Page last updated: 2024-10-16

5-aminovaleric acid and Huntington Disease

5-aminovaleric acid has been researched along with Huntington Disease in 1 studies

5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd
5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lastres-Becker, I1
de Miguel, R1
De Petrocellis, L1
Makriyannis, A1
Di Marzo, V1
Fernández-Ruiz, J1

Other Studies

1 other study available for 5-aminovaleric acid and Huntington Disease

ArticleYear
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Journal of neurochemistry, 2003, Volume: 84, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can

2003